mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.
about
Treating Elderly Patients With Hormone Receptor-Positive Advanced Breast CancerClinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trialsActivation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potentialCost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus.Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statementAromatase inhibition 2013: clinical state of the art and questions that remain to be solvedTargeting mixed lineage kinases in ER-positive breast cancer cells leads to G2/M cell cycle arrest and apoptosisEndocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway.Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trialsEverolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer.The promise of liquid biopsy in cancer: a clinical perspective.Everolimus in Breast Cancer: The Role of the Pharmacist.Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.Metastasiertes MammakarzinomEndocrine Resistance in Breast Cancer
P2860
Q26785496-16B558A8-41A2-4E64-9A4D-432E2AD55D72Q34352887-ED25D72C-03D8-4F76-812A-C18ED6675852Q34547982-B5623BBA-F6F3-4C0D-AD87-A0D51B5AABE1Q34669344-FE60B065-365C-44B0-A71F-81C8B0BC33A4Q34732945-A2E09FB8-8650-4587-8E4A-8FEC37CCBFA8Q35000248-FD8292D6-68E4-4E65-97D0-13CA37B8A600Q35053793-6370A92F-FE9C-4825-B9DE-CC065F9E9D54Q36547566-2FFD1D7B-2163-4FAD-8F36-58536907CA48Q36568571-3CFBEB7A-3DE9-4212-9841-322030B62526Q36946008-D64B29A0-BB9D-491B-A98D-D6E48C2CC3D2Q37207651-F98E4808-3DB1-42E9-98F1-A0FC9C4DA990Q37255106-76E8507A-9936-4BCF-8618-EA9C51BE6817Q37629003-C5AA0BAC-1902-44D6-88CB-693FA6DF0D83Q37690538-572CD3AB-8713-4844-ADBF-43D9132E819CQ38093128-5CBD539C-A9EB-4E40-BAF4-A88B9FCC4E6FQ38666243-D4FD1A92-5CE8-4C67-A97C-8B96CF283B9DQ40126367-791E0C61-1474-4710-A8CF-7332C534DF54Q40328327-423BA563-9E41-4993-B388-B232B18AADCFQ46458593-84A3FA55-CB6E-4B45-A9C0-F8DB51E6A9C3Q47101508-79A8C107-3592-4040-A818-81FA099E522BQ56624496-58DA3BB5-587F-4762-9CEB-5684BD5B2E3FQ59072640-E68FBF5F-B7C7-4D81-AAEB-4FBEC1053B00
P2860
mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
mTOR inhibitors in the managem ...... vidence and future directions.
@en
type
label
mTOR inhibitors in the managem ...... vidence and future directions.
@en
prefLabel
mTOR inhibitors in the managem ...... vidence and future directions.
@en
P2860
P356
P1433
P1476
mTOR inhibitors in the managem ...... evidence and future directions
@en
P2093
C Villarreal-Garza
P2860
P304
P356
10.1093/ANNONC/MDS075
P577
2012-05-02T00:00:00Z